enGene (NASDAQ:ENGN) Stock Bumped Up to “Strong-Buy” by Jefferies Financial Group

enGene (NASDAQ:ENGN) was upgraded by research analysts at Jefferies Financial Group to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

Several other research analysts have also weighed in on ENGN. Citizens Jmp reiterated a “market perform” rating on shares of enGene in a research note on Wednesday, September 9th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of enGene in a research report on Tuesday, September 8th. Wall Street Zen raised shares of enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. Morgan Stanley cut shares of enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective for the company. in a report on Thursday, June 18th. Finally, Citigroup restated a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, enGene currently has an average rating of “Hold” and an average price target of $11.05.

enGene Trading Down 4.1%

ENGN opened at $1.63 on Tuesday. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The company has a debt-to-equity ratio of 0.11, a quick ratio of 10.21 and a current ratio of 10.21. The stock has a fifty day moving average of $1.84 and a 200-day moving average of $2.90.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, research analysts predict that enGene will post -1.81 EPS for the current year.

Institutional Trading of enGene

Several large investors have recently modified their holdings of the company. Perceptive Advisors LLC raised its holdings in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after acquiring an additional 3,771,840 shares during the period. Cormorant Asset Management LP grew its position in shares of enGene by 72.1% in the fourth quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares during the last quarter. Siren L.L.C. increased its stake in shares of enGene by 57.5% in the first quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock worth $35,774,000 after purchasing an additional 1,916,895 shares during the period. Omega Fund Management LLC lifted its position in shares of enGene by 66.5% during the 4th quarter. Omega Fund Management LLC now owns 876,357 shares of the company’s stock worth $7,914,000 after purchasing an additional 350,000 shares during the last quarter. Finally, Eversept Partners LP acquired a new position in shares of enGene during the 4th quarter worth about $4,116,000. 64.16% of the stock is owned by institutional investors.

More enGene News

Here are the key news stories impacting enGene this week:

• Positive Sentiment: Analysts cited in the report have an average price target of $11.05 for enGene, substantially above the recent trading level. This suggests significant potential upside if the company executes on its development plans and investor sentiment improves. enGene Holdings Inc. Stock Has Average Target Price of $11.05
• Neutral Sentiment: The article does not identify a new clinical, regulatory, or financial catalyst. As a result, the analyst target alone may have limited immediate influence on trading, particularly given enGene’s early-stage biotechnology profile.
• Negative Sentiment: Recent investor concerns include enGene’s quarterly earnings miss, with reported loss per share of $0.47 versus the $0.43 consensus estimate, as well as continued losses expected for the full year. The shares remain below their 50-day and 200-day moving averages, indicating persistent downward momentum despite the high analyst target.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.